Real-World Data Shows Tirzepatide Drives Further Weight Loss in Already Reduced Patients

Obesity is a global health crisis, significantly increasing the risk of numerous comorbidities like type 2 diabetes and cardiovascular disease. While Tirzepatide, a dual GIP and GLP-1 receptor agonist, has demonstrated impressive weight loss in controlled clinical trials, its effectiveness in diverse, real-world settings, particularly among patients who have already achieved some weight reduction, remains less understood. This study aims to evaluate the real-world weight-loss outcomes of Tirzepatide in patients already undergoing weight management.

Over the 6-month observation period, patients treated with Tirzepatide achieved an additional mean weight loss of 10.5% from their baseline weight at the start of Tirzepatide therapy (p<0.001). Specifically, patients on the 15 mg weekly dose experienced the most significant reduction, averaging 12.8% (p<0.001) compared to 8.9% for the 5 mg dose group. A remarkable 43% of patients achieved an additional ≥15% total body weight loss from their initial weight at the start of Tirzepatide treatment, demonstrating substantial continued efficacy. This was significantly higher than the 15% observed in a matched control group (not on Tirzepatide) who continued standard weight management (p<0.001). Furthermore, 78% of patients maintained or further reduced their weight, with only 5% experiencing weight regain.